Lutetium-177
Lutetium-177 is beta-minus emitter, that is very popular in radionuclidic therapy. CMR supplies with carrier-free Lutetium-177, suitable to the requirements of EP monograph 2798 "Lutetium (177Lu) solution for radiolabeling".
Intended use
Lutetium-177 is employed for the treatment of neuroendocrine tumors with metastases. The therapy involves labeling ligands with the radioactive nuclide Lutetium-177. The medication is administered intravenously. Additionally, the patient receives a protective agent to reduce radiation exposure. The medication exerts a potent impact on cancer cells with the goal of their destruction. In some cases, complete recovery occurs, but predominantly Lutetium-177 is used to alleviate clinical manifestations of cancer.
CMR Product code: R001
Grade:
1. Non-carrier added radionuclide;
2. GMP product;
3. Tested for sterility and bacterial endotoxins.
Chemical form: Lutetium chloride (LuCl3), solution in hydrochloric acid 0.04M
Appearance: transparent, colourless liquid
Half-life period: 6.734 days
Radiochemical purity, %: ≥ 99.0
Specific activity, Ci/mg: > 81.08
Intended use
Lutetium-177 is employed for the treatment of neuroendocrine tumors with metastases. The therapy involves labeling ligands with the radioactive nuclide Lutetium-177. The medication is administered intravenously. Additionally, the patient receives a protective agent to reduce radiation exposure. The medication exerts a potent impact on cancer cells with the goal of their destruction. In some cases, complete recovery occurs, but predominantly Lutetium-177 is used to alleviate clinical manifestations of cancer.
CMR Product code: R001
Grade:
1. Non-carrier added radionuclide;
2. GMP product;
3. Tested for sterility and bacterial endotoxins.
Chemical form: Lutetium chloride (LuCl3), solution in hydrochloric acid 0.04M
Appearance: transparent, colourless liquid
Half-life period: 6.734 days
Radiochemical purity, %: ≥ 99.0
Specific activity, Ci/mg: > 81.08
Other products
